Abcellera Biologics Inc ABCL

$12.16 +0.45 (3.84%)

Valuation

Market cap
3,657,870,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
1,889,632
Avg volume
6,204,052
Day's range
$11.59 – $12.23
Shares out
306,611,000
Stochastic %K
18%
Beta
1.41
Analysts
Strong Sell
Price target
$16.82

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

Stocktradesmoon Oct 21, 5:25 PM
$ABCL ABcellera 🔥 🔥!!! BREAK-OUT MODE!! WAVE 5 Price TARGET 🎯 $21.69!!! Major Catalyst tomorrow Phase 2 Results-the 12 WEEK DATA 📊 UPDATE ABcellera: I’ve shared my short-term PT expectations and resistance levels before. Adding this: If the market fully prices in ABCL’s 5–10 year potential during this rally, we could see a sharp move into the $36–52 range, followed by a meaningful pullback afterward (low probability scenario). That said, the long-term potential remains massive. Success in internal programs + external partnerships could reasonably drive this to a $100+ stock by 2029. It’s a matter of execution and time.
2 replies
Stocktradesmoon Oct 21, 5:22 PM
$ABCL Don’t forget what Carl said about listening to others, both in life and in markets, unless you want to be blown off course... Imagine getting the chance to own Regeneron right before it exploded into a giant... that’s the opportunity you have today. At a similar crossroad, Regeneron did not have AI as a tailwind, they had less money and more debt, and slower initial clinical validation, and was significantly less internally diversified both technologically and programmatically. Nobody here can convince you of this... You have to do the work to research and develop your own conviction! Simply borrowing it from others will not suffice... I jumped down the rabbit hole and researched, read and watched everything‼️ Now I can’t stop buying, and I look at anyone trimming this name and can’t help but feel bad for them...truly. I remain 100% full ported on ABCL ... 🫡 TLDR: I will gladly buy your dollars for pennies
0 replies
Stocktradesmoon Oct 21, 5:21 PM
$ABCL 😮 🤯 👀🚨Not just a repeat of the known Topline‼️ $ABCL First batch of New Data incoming, AbCellera will be presenting more Phase 1/2 data for ABCL635 at The Menopause Society’s 2026 Annual Meeting on Oct 22. AbCellera will present safety, pharmacokinetics, pharmacodynamics, and efficacy data from its Phase 1/2 trial. This includes new safety data from the Phase 1 multiple ascending dose study, as well as new patient-reported outcome data from the Phase 2 study. As a reminder, the trial included a parallel Multiple Ascending Dose (MAD) segment in which 16 postmenopausal women received 3 consecutive once-monthly injections of either 300mg or 600mg. Small sample size, but hoping the additional data reinforces flat liver enzymes, predictable steady-state accumulation, sustained biomarker suppression, and low immunogenicity. Read more about ABCL635 here: https://abcellera.com/pipeline/abcl635
0 replies
Stocktradesmoon Oct 21, 5:19 PM
$ABCL
0 replies
erpy Oct 21, 5:17 PM
$ABCL Jmho but i follow the money when I see 1M shares bought yesterday that says something. That Something, is something I dont know. I follow the money. You do you!!!
1 replies
Stocktradesmoon Oct 21, 5:14 PM
$ABCL
0 replies
erpy Oct 21, 5:11 PM
$ABCL Another day the shorts hold the price down as best they can. I think the pressure is building and they wont be successful much longer. I conclude this just from watching the tape. These insiders buy for 1 reason and 1 reason only. Its going higher. Jmho.. The tape showed over a $12 Million buy yesterday. You think that guy expecting to loose. Dont fall for the short shenanigans. $12.5 very soon imho.
0 replies
Stocktradesmoon Oct 21, 5:06 PM
$ABCL 13’sss up NEXT!! 👀🚨1 Day 🔥!! Why is the Conference tomorrow Evening/Night?!! Because They are ABOUT to DROP News 🗞️ and BURN 🔥 those 40 Million Shorts!!! They are going to TRAP them for Friday Morning!! Carl CEO ❤️ to burn 🔥 shorts on Friday’s and Over the Weekend!!!! 😮 🤯
0 replies